GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » EV-to-Revenue

Laurus Labs (BOM:540222) EV-to-Revenue : 5.17 (As of Jun. 08, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Laurus Labs's enterprise value is ₹260,502 Mil. Laurus Labs's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹50,408 Mil. Therefore, Laurus Labs's EV-to-Revenue for today is 5.17.

The historical rank and industry rank for Laurus Labs's EV-to-Revenue or its related term are showing as below:

BOM:540222' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.35   Med: 3.43   Max: 7.74
Current: 5.16

During the past 11 years, the highest EV-to-Revenue of Laurus Labs was 7.74. The lowest was 1.35. And the median was 3.43.

BOM:540222's EV-to-Revenue is ranked worse than
77.84% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 2.275 vs BOM:540222: 5.16

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-08), Laurus Labs's stock price is ₹438.15. Laurus Labs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₹93.17. Therefore, Laurus Labs's PS Ratio for today is 4.70.


Laurus Labs EV-to-Revenue Historical Data

The historical data trend for Laurus Labs's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs EV-to-Revenue Chart

Laurus Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 4.42 6.84 2.94 4.67

Laurus Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 3.47 4.38 4.65 4.67

Competitive Comparison of Laurus Labs's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Laurus Labs's EV-to-Revenue falls into.



Laurus Labs EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Laurus Labs's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=260501.953/50408.3
=5.17

Laurus Labs's current Enterprise Value is ₹260,502 Mil.
Laurus Labs's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹50,408 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laurus Labs  (BOM:540222) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Laurus Labs's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=438.15/93.165
=4.70

Laurus Labs's share price for today is ₹438.15.
Laurus Labs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹93.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laurus Labs EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Laurus Labs's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Laurus Labs (BOM:540222) Business Description

Traded in Other Exchanges
Address
Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines